GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wright Medical Group Inc (FRA:WM3) » Definitions » EV-to-EBITDA

Wright Medical Group (FRA:WM3) EV-to-EBITDA : -14.91 (As of Jun. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Wright Medical Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Wright Medical Group's enterprise value is €1,086.9 Mil. Wright Medical Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2015 was €-72.9 Mil. Therefore, Wright Medical Group's EV-to-EBITDA for today is -14.91.

The historical rank and industry rank for Wright Medical Group's EV-to-EBITDA or its related term are showing as below:

FRA:WM3's EV-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 16.09
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Wright Medical Group's stock price is €18.87. Wright Medical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2015 was €-4.422. Therefore, Wright Medical Group's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Wright Medical Group EV-to-EBITDA Historical Data

The historical data trend for Wright Medical Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wright Medical Group EV-to-EBITDA Chart

Wright Medical Group Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.85 - - - -

Wright Medical Group Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.32 -22.51 - - -

Competitive Comparison of Wright Medical Group's EV-to-EBITDA

For the Medical Devices subindustry, Wright Medical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wright Medical Group's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Wright Medical Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Wright Medical Group's EV-to-EBITDA falls into.



Wright Medical Group EV-to-EBITDA Calculation

Wright Medical Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1086.921/-72.911
=-14.91

Wright Medical Group's current Enterprise Value is €1,086.9 Mil.
Wright Medical Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €-72.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wright Medical Group  (FRA:WM3) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Wright Medical Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=18.87/-4.422
=At Loss

Wright Medical Group's share price for today is €18.87.
Wright Medical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.422.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Wright Medical Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Wright Medical Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Wright Medical Group (FRA:WM3) Business Description

Traded in Other Exchanges
N/A
Address
Wright Medical Group Inc, through Wright Medical Technology, Inc. and other operating subsidiaries, is a specialty orthopaedic company, that provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients' lifestyles. The Company provides surgical solutions for the foot and ankle market and markets its products in over 60 countries. Its business includes products that are used in foot and ankle repair, upper extremity products, and biologics products, which are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and their patients. Extremity hardware includes implants and other devices to replace or reconstruct injured or diseased joints and bones of the foot, ankle, hand, wrist, fingers, toes, elbow and shoulder, which it generally refer to as either foot and ankle or upper extremity products. The Company's manufacturing and warehousing operations are located in Arlington, Tennessee. Outside the U.S., The Company has distribution and administrative facilities in Amsterdam, the Netherlands, and sales and distribution offices in Canada, Australia, and Europe. The Company operates its continuing operations as one reportable segment and offer products in extremity reconstruction and biologics. The Company's products include CHARLOTTE, CLAW II, DARCO, EVOLVE, MICRONAIL, GRAFTJACKET, OSTEOSET. Its competitors include major companies in the orthopaedic and biologics industries, as well as academic institutions and other public and private research organizations that continue to conduct research, seek patent protection and establish arrangements for commercializing products. The Company's products are strictly regulated by the FDA under the Food, Drug, and Cosmetic Act. Some of its products are also regulated by state agencies.

Wright Medical Group (FRA:WM3) Headlines

No Headlines